non-small cell lung cancer
Conditions
Interventions
None listed
Sponsors
Yokohama City University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion Criteria, Publication Type, and Trial Design We focus on patient-level randomized controlled trials (RCTs) for early-stage and locally-advanced NSCLC. Trials that recruit patients with driver mutations or translocations will be excluded, whereas those with driver negative patients is accepted Conference abstracts will be included to reflect recent research data. An article written in non-English language will be excluded. Inclusion Criteria, Patients Patients with NSCLC indicated for NAC will be included, covering both early-stage and locally advanced diseases. We will not regulate the pathological subtype of NSCLC (i.e., squamous, non-squamous, adenocarcinoma). However, RCTs primarily targeting large cell neuroendocrine carcinoma will be excluded as such cancer is typically treated following a small-cell lung cancer protocol. No restrictions will be set on performance status (PS) or age. Inclusion Criteria, Treatment Eligible treatments will include standalone NAC and combined NAC and AC, incorporating at least one ICI medication. The regimen may include cytotoxic agents and molecular targeted therapies as long as it includes ICI. Any platinum doublet chemotherapy combining one of the platinum agents (cisplatin [CDDP], carboplatin [CBDCA], oxaliplatin, nedaplatin, or lobaplatin) with other cytotoxic agents will collectively be regarded platinum doublet therapy, reflecting the common practice of allowing physician preference among platinum doublets. RCTs examining standalone AC and RCTs focused on radiotherapy will be excluded from our review.
Exclusion criteria
Exclusion criteria: None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The co-primary outcomes of this analysis will be the hazard ratio (HR) for overall survival (HRos) and, the HR for event-free survival (EFS, HRefs). Although progression-free survival (PFS), recurrence-free survival (RFS), and disease-free survival (DFS) are not identical to EFS, these outcomes will be analyzed collectively due to their conceptual similarity, especially for patients with successful surgical removal. Additionally, the odds ratio (OR) for surgical resection rate, complete surgical removal of a tumor with no visible or microscopic cancer cells left at the margins of the resected tissue (R0 resection), major pathological response (MPR), any grade treatment-related adverse event (any TRAE), grade 3 or higher TRAE (>= G3 TRAE), grade 5 AE, serious AE, and AE leading to surgery cancellation will also be analyzed. | — |
Countries
Japan
Contacts
Public ContactNobuyuki Horita
Yokohama City University Hospital Chemotherapy Center
Outcome results
None listed